These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9180194)

  • 1. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
    Imrie A; Beveridge A; Genn W; Vizzard J; Cooper DA
    J Infect Dis; 1997 Jun; 175(6):1502-6. PubMed ID: 9180194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D
    J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
    Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
    J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
    Parham L; de Rivera IL; Murillo W; Naver L; Largaespada N; Albert J; Karlsson AC
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1055-9. PubMed ID: 21417948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
    Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
    AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    van Zyl GU; Claassen M; Engelbrecht S; Laten JD; Cotton MF; Theron GB; Preiser W
    J Med Virol; 2008 Jun; 80(6):942-6. PubMed ID: 18428139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
    de Ronde A; van Dooren M; van Der Hoek L; Bouwhuis D; de Rooij E; van Gemen B; de Boer R; Goudsmit J
    J Virol; 2001 Jan; 75(2):595-602. PubMed ID: 11134272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
    Yap SH; Herman BD; Radzio J; Sluis-Cremer N; Tachedjian G
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):153-7. PubMed ID: 22743599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
    Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper DA; Yerly S
    AIDS; 2000 May; 14(8):1065-7. PubMed ID: 10853993
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA; Reedijk M
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract]   [Full Text] [Related]  

  • 19. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
    Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
    J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper P; Imrie A; Weigel HM; Kauffmann RH; Koster R
    J Infect Dis; 1994 Jun; 169(6):1346-50. PubMed ID: 8195615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.